JHL will be participating in the COVID-19 Virtual Partnering Event on May 4-6. Welcome to meet us virtually to tackle the virus together! Visit the Event website: https://virtual-partnering.com/ Contact Us:... read more →
HSINCHU, Taiwan, February 26, 2020 — With a globally-focused enthusiasm and aspiration to build sustainable and reputable CDMO facilities for the China Biologics Market, JHL Biotech has made a strategic... read more →
JHL’s AD-Bio Lab has recently been fitted with additional working space, including three working benches for new equipment purchases and expanded Analytical Capabilities. Due to JHL’s need for additional capacity,... read more →
HSINCHU, Taiwan and WUHAN, China, August 16, 2019 -- JHL Biotech has reached a settlement agreement with Genentech to resolve Genentech’s civil claims related to the development of certain biologic... read more →
HSINCHU, Taiwan and WUHAN, China, June 13, 2018 /PRNewswire/ -- JHL Biotech has raised US$106 million in a convertible bond issuance, which closed May 15, 2018. Proceeds raised from the... read more →
HSINCHU, Taiwan and WUHAN, China, February 3, 2018 -- JHL Biotech (TPEx: 6540) announced that the Taipei Exchange (“TPEx”) granted approval on February 2 for the termination of trading of... read more →
HSINCHU, Taiwan and WUHAN, China, January 1, 2018 -- JHL Biotech announced that Rong Chen has been appointed Chief Medical Officer effective January 1. As CMO, Dr. Chen will oversee... read more →
JHL Biotech, Inc. (“JHL”, 6540. TWO) was awarded a top 20 ranking in Deloitte Touche Tohmatsu Limited’s 2017 Asia Technology Fast 500™ list. This annual ranking compares the fastest growing... read more →
Singapore and Hsinchu, Taiwan, 14 November 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, and JHL Biotech,... read more →